Cardinal Health (CAH) Q2 2026 earnings review
Broad-Based Beat Drives Guidance Raise
Cardinal Health delivered a robust Q2, with Non-GAAP EPS surging 36% YoY to $2.63, significantly outpacing the 19% revenue growth. All segments contributed to double-digit profit expansion, led by the 'Other' segment (+52%) and a continued recovery in GMPD (+106%). The integration of Solaris Health and strong specialty performance fueled the Pharma segment. Management raised FY26 Non-GAAP EPS guidance by $0.50 at the midpoint to $10.15–$10.35, signaling confidence in sustained momentum despite rising interest costs and tariff headwinds.
🐂 Bull Case
The Pharmaceutical segment profit grew 29%, driven by the acquisition of MSO platforms (Solaris, GI Alliance) and specialty products. These higher-margin services are successfully diversifying earnings away from low-margin distribution.
The 'Other' segment (Nuclear, at-Home, OptiFreight) is proving to be a hidden gem, with profit exploding 52% YoY. The acquisition of Advanced Diabetes Supply and strong demand for Theranostics are creating a powerful new growth engine.
🐻 Bear Case
While Global Medical Products (GMPD) profit improved YoY, it remains sensitive to tariffs. Management explicitly noted an 'adverse net impact' from tariffs in Q2. Segment profit ($37M) actually declined sequentially from Q1 ($46M), highlighting fragility.
To fund aggressive M&A like Solaris, Cardinal has levered up. Interest expense more than doubled YoY to $88M in Q2. While coverage remains comfortable, this creates a higher hurdle for net income growth compared to operating earnings.
⚖️ Verdict: 🟢🟢
Bullish. Cardinal Health is executing a successful pivot to higher-margin specialty services. The massive 36% EPS growth, combined with a significant guidance raise and robust cash flow ($686M OCF vs negative last year), outweighs concerns over tariffs and interest expense.
Key Themes
Pharmaceutical & Specialty Dominance
Accelerating. Pharma segment profit grew 29% to $687M, accelerating from +26% in Q1. This was driven by brand/specialty volume and the MSO platform strategy (Solaris, GIA). The company raised full-year segment growth guidance to 20-22%, confirming that the benefits from M&A and generics program performance are durable.
'Other' Segment Explosion
Accelerating. The 'Other' segment (at-Home, Nuclear, OptiFreight) has become a star performer. Revenue jumped 34% and profit surged 52% to $179M. The integration of Advanced Diabetes Supply is driving at-Home Solutions, while Nuclear and Precision Health continues to capitalize on theranostics demand. Guidance for this segment was raised to 33-35% growth.
GMPD Tariff Exposure
Recovering but Vulnerable. Global Medical Products and Distribution (GMPD) profit doubled YoY to $37M due to cost optimization and easy comps ($18M in 25Q2). However, profit declined sequentially from $46M in 26Q1. Management cited an 'adverse net impact of tariffs,' partially offsetting cost savings. The full-year outlook was tweaked to ~$150M, suggesting limited upside from here due to trade headwinds.
Financing Costs from M&A
Interest expense spiked to $88M in Q2 from $35M in the prior year, driven by debt taken on to fund the Solaris and other acquisitions. While the acquisitions are accretive to Operating Earnings, this line item creates a drag on Net Income flow-through.
Cash Flow Turnaround
Operating Cash Flow swung dramatically to positive $686M in Q2, compared to a usage of $396M in the prior year period. This normalization supports the company's capital allocation strategy, including the completion of a $375M accelerated share repurchase in the quarter.
Other KPIs
Up 23% YoY. Margin expansion is outpacing revenue growth (19%), indicating favorable mix shift toward higher-margin specialty services and medical products, rather than just bulk distribution.
Up 15% YoY. Expenses are growing slower than Gross Profit (+23%) and Revenue (+19%), demonstrating operating leverage despite the integration costs associated with recent acquisitions.
Increased from 21.4% a year ago. Management cited a 'lower share count' benefit to EPS, but the tax headwind partially dampens the bottom-line growth. Non-GAAP tax rate remained flat at 21.4%.
Guidance
Accelerating. Raised significantly from the prior range of $9.65-$9.85. The new midpoint ($10.25) implies ~24% YoY growth. This reflects the immediate accretion from Solaris and broad-based segment strength.
Accelerating. Raised from 16-19%. This suggests the momentum seen in Q2 (29% growth) is largely durable through the second half, driven by specialty/MSO contribution.
Stable. Previously guided to 'at least $140 million.' While technically a slight raise/narrowing, the lack of significant upside revision here confirms that tariffs remain a cap on the recovery speed.
Accelerating. Raised from 29-31%. The integration of Advanced Diabetes Supply is outperforming, and nuclear demand shows no signs of slowing.
Key Questions
GMPD Tariff Mitigation
With GMPD profit stepping down sequentially and tariffs cited as an adverse impact, how much of the ~$150M FY26 profit target is at risk if new tariff policies are enacted before fiscal year-end?
Integration Speed
The Pharma segment guide raise is substantial. How much of this is driven by better-than-expected synergies from Solaris/GIA versus organic core distribution outperformance?
Cash Flow Cadence
Despite the OCF improvement in Q2, Free Cash Flow remains impacted by M&A outflows. What is the normalized Free Cash Flow conversion rate expected for FY27 once integration costs settle?